bioihbjkbjnl/mcl2 huggingface dataset:
Real and Sham Diathermy vs Hand Massage in Lower Limbs Delayed Onset Muscle Soreness (DOMS)Effect on Knee Proprioception
Condition: Musculoskeletal Pain
MeSH terms: Musculoskeletal Pain; Myalgia; Hyperthermia
Study type: Interventional

Summary: 
      Delayed onset muscle soreness (DOMS) can have an impact on the proprioception of knee joint .
      The study aim is to assess the effect of manual massage, diathermy and sham diathermy the
      proprioception of the knee joint in patients affected by DOMS.
    

Detailed description: 
      Delayed onset muscle soreness (DOMS) can have an impact on the proprioception of knee joint.
      The study aim is to assess the effect of manual massage, diathermy and sham diathermy on the
      proprioception of the knee joint in patients affected by DOMS.

      Proprioception will be measured with "Technique" an App available on appstore , on the basis
      of the work on knee proprioception by S M Mir 2008 , and data about pain with numbering pain
      rating scale (NPRS) and pre-post treatment and global impression of change (PGIC) will be
      acquired.
    

Intervention name(s): Massage; DIathermy; Sham diathermy
Intervention type(s): Other; Device; Device
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: Proprioception; Doms; Pain; Massage; Diathermy
Multi-Sensory Training and Wrist Fractures
Condition: Postural Balance
MeSH terms: Wrist Fractures
Study type: Interventional

Summary: 
      The aim of the study is to investigate whether individuals with fall-related wrist fractures
      have impaired posterior control, reduced proprioception in their lower limbs and/or
      vestibular asymmetry compared with those who have not fallen and sustained a fracture.
      Secondly to investigate the effects of a new balance training method, directed at the sensory
      systems and training of fall-preventive movements on postural control and how it impacts the
      function of the sensory systems. Postural instability falls and fractures form one of the
      major problems associated with ageing. An association of vestibular- asymmetry with falls and
      fractures has been found and reduced vibration sensation in the lower limbs has been
      connected with imbalance. Wrist fractures are often precursor to the more serious hip
      fractures, which often result in decreased quality of life, even death and are costly for the
      society. Subjects will be individuals 50-75 years of age having sustained a fall-related
      wrist fracture. Measurements of sensory functions, postural control and functional ability
      will be conducted before and after balance training. Confidence in daily activities and
      self-perceived dizziness handicap will be obtained with questionnaires. The same evaluations
      will be performed on age and gender matched individuals without previous history of
      fall-related wrist fractures. This research might reveal the presence and frequency of
      vestibular asymmetry or/and other age related degenerative changes in the sensory systems,
      which decrease stability and increase the risk of falls and fractures. It could show
      preventive effects of specific balance training on fall risk, and thus increase quality of
      life of the individuals, improve healthcare services and decrease costs associated with falls
      and fractures.
    


Intervention name(s): Multi-Sensory Training
Intervention type(s): Other
Other intervention name(s): Wrist Stabilisation Training
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Investigator, Outcomes Assessor)
Primary purpose: Treatment
Keywords: fracture; rehabilitation; wrist; sensation; exercise
Evaluation of Increased Absorption of a Curcumin Emulsion (CurQ+) in Healthy Volunteers
Condition: Bioavailability
Study type: Interventional

Summary: 
      This study is intended to evaluate the comparative effects of direct analysis of serum
      samples versus pre-treatment with enzymatic hydrolysis in split samples obtained from dosing
      with a highly absorbed curcumin emulsion product that is commercially available as BIOCURC.
    

Detailed description: 
      When curcumin is absorbed by the body, it is primarily found in the bloodstream as curcumin
      glucuronide (C-gluc) and curcumin sulfate (C-SO4) metabolites. Traditionally bioavailability
      studies have performed an enzymatic hydrolysis pre-treatment of serum samples with both a
      glucuronidase and a sulfatase enzyme in order to produce free curcumin for analysis via HPLC.
      In subsequent years, standards have become available for the metabolites (C-gluc & C-SO4)
      that make it possible to determine these compound levels directly in serum samples using
      HPLC-MS-MS. Initial pilot work had indicated that enzymatic hydrolysis was producing falsely
      elevated results for bioavailability. We wanted to evaluate this in a more formal setting.
    

Intervention name(s): 95% Curcuminoid Powder; CurQ+
Intervention type(s): Dietary Supplement; Dietary Supplement
Intervention description(s): 1200 mg curcuminoids; 400 mg curcuminoids + coconut oil + polysorbate
Allocation: Randomized
Intervention model: Crossover Assignment
Intervention model description: open-label, crossover
Masking: None (Open Label)
Primary purpose: Basic Science
Keywords: Bioavailability; Absorption
A Study of IMR-687 in Adult Participants With Sickle Cell Anemia (Homozygous HbSS or Sickle-β0 Thalassemia)
Condition: Sickle Cell Disease
MeSH terms: Anemia, Sickle Cell; Thalassemia
Study type: Interventional
Phase: Phase 2

Summary: 
      Study of IMR-687 in adult participants with sickle cell anemia (SCA) (homozygous HbSS or
      sickle-β0 thalassemia).
    

Detailed description: 
      This is a proof-of-concept study in adult SCA participants, ages 18 to 55 years old, to
      examine the safety, tolerability, and pharmacokinetic (PK), as well as the potential
      pharmacodynamic (PD) effects and clinical efficacy, of IMR-687 across a range of doses.

      IMR-687 was administered in 2 populations of participants with SCA: those who were not
      receiving hydroxyurea (HU) and those who were receiving a stable dose of HU according to
      standard of care.
    

Intervention name(s): IMR-687; Placebo
Intervention type(s): Drug; Drug
Intervention description(s): Oral administration of IMR-687 once daily with or without HU.; Oral administration of placebo once daily with or without HU.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Remifentanil Dosing Regimes for Anesthesia in Bariatric Surgery: Characteristics of Early Recovery
Condition: Morbid Obesity
MeSH terms: Obesity, Morbid
Study type: Observational [Patient Registry]

Summary: 
      Early recovery characteristics are important for patients' safety and operating room
      turnover. Our aim was to compare fundamental methods for dosing remifentanil during morbid
      obesity surgeries: a manual infusion and a target-controlled infusion (TCI). Throughout
      study, patient's recovery time was tracked and compared between the groups.
    

Detailed description: 
      Introduction: The population of overweighted patients is increasing dramatically, therefore
      physicians face them in their daily practice (1-2). There are many guidelines showing the
      dose counting methods of intravenous anesthetics, but none of them are perfectly good for
      morbidity obese patients (3). Early recovery characteristics are important for patients'
      safety and operating room turnover (4).

      Aim: Our aim was to compare fundamental methods for dosing remifentanil during morbid obesity
      surgeries: a manual infusion and a target-controlled infusion (TCI). Throughout study,
      patient's recovery time was tracked and compared between the groups.

      Methods: 31 patients were evaluated who underwent bariatric surgery in Hospital of Lithuanian
      University of Health Sciences. All of them had received sevoflurane/remifentanil anaesthesia.
      Remifentanil infusion was randomly assigned to a manual (control group) or to a TCI (case
      group) method. We had evaluated patients' hemodynamics (arterial blood pressure, heart rate,
      saturation), spontaneous breathing and airway reflexes recovery time, time of extubation, eye
      opening, recovery of orientation and start of the following oral command. Also we had
      registered concentrations of remifentanil in the blood (according to automatic infusion pump)
      while using TCI method.
    

Observational model: Cohort
Time perspective: Prospective
Sampling method: Non-Probability Sample
Study population: 
        Patients with morbid obesity who are hospitalised in Hospital of Lithuanian University of
        Health Sciences Kaunas Clinics for laparoscopic bariatric surgery.
      
Keywords: morbid obesity; remifentanil; manual infusion; target - controlled infusion
Third Ventricle Echographic Study for Neuro-intensive Care Unit Patients
Condition: Neuro-intensive Care Unit Patients; Brain Injuries
MeSH terms: Brain Injuries
Study type: Observational

Summary: 
      Transcranial Doppler ultrasonography is usually used in the evaluation and management of
      patients with brain injury. This noninvasive method measures local blood flow velocity and
      direction in the proximal portions of large intracranial arteries. The operator requires a
      short training and experience to perform. The third ventricle diameter measurement by
      transcranial duplex flow sonography was performed in healthy volunteers . This studies show
      similar results in those obtained with the MRI or Computer Tomography (CT). Currently the
      third ventricle diameter measurements by transcranial Doppler ultrasonography was not
      validated for neuro-intensive care unit patients. The investigators propose to used recent
      ultrasound system to validate the third ventricle diameter measurements in comparison with
      the standard method (CT).
    

Detailed description: 
      Transcranial Doppler ultrasonography is usually used in the evaluation and management of
      patients with brain injury. This noninvasive method measures local blood flow velocity and
      direction in the proximal portions of large intracranial arteries. The operator requires a
      short training and experience to perform. The third ventricle diameter measurement by
      transcranial duplex flow sonography was performed in healthy volunteers . This studies show
      similar results in those obtained with the MRI or Computer Tomography (CT). Currently the
      third ventricle diameter measurements by transcranial Doppler
    

Intervention name(s): Transcranial Doppler ultrasonography measurements
Intervention type(s): Device
Intervention description(s): Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
Observational model: Other
Time perspective: Prospective
Sampling method: Probability Sample
Study population: 
        All patients admitted to the neurointensive care
      
Keywords: Neuro-ICU; Third ventricle; Computer Tomography; Transcranial Doppler ultrasonography
Correlation of Spinopelvic Movement With Lateral Radiographs
Condition: Spinopelvic Relationships as They Relate to Total Hip Arthroplasty's
Study type: Interventional

Summary: 
      The purpose of this research is to compare a novel pelvic MetaWear sensor that looks at spine
      and pelvic movements when taking lateral sit-to-stand radiographs.
    


Intervention name(s): MetaWear Sensor
Intervention type(s): Device
Intervention description(s): Sensor placed on the pelvis to record spinopelvic movement. Lateral sitting and standing lumbar radiographs will be taken
Intervention model: Single Group Assignment
Intervention model description: All participants will have the MetaWear Sensors used on them
Masking: None (Open Label)
Primary purpose: Health Services Research
Inactive HBsAg Carriers (IHCs) Treated With Pegylated Interferon α2b Based Intervention Therapy
Condition: Chronic Hepatitis B
MeSH terms: Hepatitis A; Hepatitis B; Hepatitis B, Chronic; Hepatitis
Study type: Interventional

Summary: 
      A single center, randomized controlled trial design was used to select patients with chronic
      hepatitis B in the immune control period (HBsAg positive, HBeAg negative, normal ALT, HBsAg ≤
      1500iu/ml, HBV DNA ≤ 2000iu/ml) to enter the study, and to compare the feasibility,
      effectiveness and safety of pegylate combined with Granulocyte-macrophage colony stimulating
      factor, high-dose hepatitis B vaccine and pegylate monotherapy in the treatment of patients
      with chronic hepatitis B in the immune control period
    

Detailed description: 
      Explore the efficacy, safety and related influencing factors of intervention therapy based on
      PegIFN α- 2b in inactive hepatis B surface antigen (HBsAg) carriers (IHCs), and compare
      pegifn α- 2b combined with granulocyte macrophage stimulating factor (GM-CSF), high-dose
      hepatitis B vaccine and pegifn α- 2B feasibility, efficacy and safety of monotherapy for
      IHCs.The IHCs patients were randomly divided into two groups (group A: pegifn α- 2b single
      drug group, group B: pegifn α- 2b combined with GM-CSF and high-dose hepatitis B vaccine
      group). To start applying pegifn α- 2B was the baseline, treatment for 68 weeks, followed up
      for 24 weeks after drug withdrawal. Patients in group B used GM-CSF and vaccine introduction
      for 16 weeks before baseline.The HBsAg clearance rate and related influencing factors of the
      two groups at 68 weeks were analyzed.
    

Intervention name(s): PegIFN α- 2b
Intervention type(s): Drug
Intervention description(s): Adjuvant immunotherapy with GM-CSF and Hepatitis B vaccine
；GM-CSF（100 μg/ piece, produced by Xiamen Tebao Bioengineering Co., Ltd）；Hepatitis B vaccine（Each 1.0ml/HBsAg60 μ g. Shenzhen Kangtai Biological Products Co., Ltd）
Other intervention name(s): pegbin ® 180μg，produced by Xiamen Tebao Bioengineering Co., Ltd.
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: inactive hepatitis B virus carriers; HBsAg clearance; peginterferon alpha 2b; Intervention treatment
A Cross Over Study to Compare the Effect of Combined Treatment With QAV680 and Cetirizine
Condition: Allergic Rhinitis
MeSH terms: Rhinitis; Rhinitis, Allergic
Study type: Interventional
Phase: Phase 2

Summary: 
      This study will determine the capacity of more frequent dosing of QAV680 to suppress allergic
      inflammation. The study will investigate the paradigm of multiple receptor antagonism in
      allergic disease by combining QAV680 with a second generation H1 histamine receptor
      antagonist to assess possible additive or synergistic anti-allergic effects of the two
      compound classes.
    


Intervention name(s): QAV680 + Cetirizine Placebo; QAV680 + Cetirizine; Cetirizine + QAV680 Placebo; QAV680 Placebo + Cetirizine Placebo
Intervention type(s): Drug; Drug; Drug; Drug
Intervention MeSH terms: Cetirizine
Allocation: Randomized
Intervention model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary purpose: Treatment
Keywords: Allergic inflammation; Seasonal rhinitis
Efficacy and Safety of BI 655066/ABBV-066 (Risankizumab) in Patients With Severe Persistent Asthma
Condition: Asthma
MeSH terms: Asthma
Study type: Interventional
Phase: Phase 2

Summary: 
      The objectives of this trial are primarily to evaluate the efficacy and safety of BI
      655066/ABBV-066 (risankizumab) as compared to placebo over a 24-week treatment period in
      severe asthma patients. The primary endpoint is time to first asthma worsening during the
      planned 24 week treatment period for active vs. placebo treated patients on top of standard
      of care therapy. Upon demonstration of a meaningful clinical response, another important
      objective is the identification of biomarkers that can be used to target patients who will
      likely respond to treatment with BI 655066/ABBV-066 (risankizumab).
    


Intervention name(s): placebo; risankizumab
Intervention type(s): Drug; Drug
Intervention description(s): Matching placebo for risankizumab; Monoclonal IgG antibody
Other intervention name(s): ABBV-066; BI 655066
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary purpose: Treatment
Environmental & Genetic Influences on Vitamin D Status
Condition: Vitamin D Deficiency
MeSH terms: Vitamin D Deficiency
Study type: Observational

Summary: 
      The purpose of this study is to determine the effect of environmental and genetic influences
      on Vitamin D status.
    

Detailed description: 
      Vitamin D deficiency is a common problem. The principal source of vitamin D for humans is
      solar exposure, with cutaneous synthesis of vitamin D by photoconversion of
      7-dehydrocholesterol in the skin to pre-vitamin D3. Latitude, altitude, season, skin
      pigmentation, and age are recognized factors that influence how much vitamin D can be made by
      solar exposure. Surprisingly, Vitamin D deficiency has been described in people dwelling in
      southern Florida and in surfers in Hawaii. We hypothesize that genetic variations in vitamin
      metabolism accounts for these differences.
    

Observational model: Cohort
Time perspective: Cross-Sectional
Sampling method: Non-Probability Sample
Study population: 
        This study will include 50 "healthy" unrelated community dwelling males or females.

        The subjects will be between ages 18-60.
      
Biospecimen description: 
      Blood was obtained for genetic testing of selected 13 candidate genes important for vitamin D
      metabolism
    
Keywords: Vitamin D deficiency; Sun; Genetics
Granulocyte Colony-stimulating Factor (G-CSF) Plus or Minus AMD3100 for Engraftment Post Allogeneic Transplant
Condition: Stem Cell Transplant Patients
Study type: Interventional
Phase: Phase 1

Summary: 
      Patients who have not had adequate blood count recovery post related or unrelated stem cell
      transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully
      improve their blood counts.
    

Detailed description: 
      Patients who have not had adequate blood count recovery post related or unrelated stem cell
      transplant will be given a "boost" of T-cell depleted, enriched stem cells to hopefully
      improve their blood counts.

      The unrelated donors will receive G-CSF prior to pheresis (collection of the stem cells) to
      boost the number of CD34+ cells. The related donors will receive G-CSF and AMD3100 prior to
      pheresis to boost the number of CD34+ cells. Once the CD34+ cells are collected they will be
      T-cell depleted using a cell separation device called the CliniMACS systems. The CliniMACS
      system will select the CD34+ cell and remove the T-cells. By removing the T-cells we can
      minimize the risk of Graft Versus Host Disease (GVHD). The enriched CD34+ cells will be given
      to them to hopefully give them a "boost" of cells that can permanently produce new blood
      cells to improve their risk of infection and bleeding.
    

Intervention name(s): G-CSF; AMD3100; Leukapheresis; Stem Cell Infusion
Intervention type(s): Drug; Drug; Procedure; Procedure
Intervention description(s): Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
Other intervention name(s): Neupogen; Plerixafor; Mozobil
Intervention MeSH terms: Plerixafor
Allocation: Non-Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Randomized Trial With Vinorelbine and Gemcitabine Versus Docetaxel and Gemcitabine in Patients With Non-Small Cell Lung Cancer
Condition: Non Small Cell Lung Cancer
MeSH terms: Lung Neoplasms; Carcinoma, Non-Small-Cell Lung
Study type: Interventional
Phase: Phase 3

Summary: 
      The purpose of this study is to evaluate whether the gemcitabine/vinorelbine combination
      versus the gemcitabine/docetaxel combination as first line treatment, offers a survival
      advantage in patients with locally advanced/metastatic NSCLC.
    

Detailed description: 
      Cisplatin-based chemotherapy represented the backbone of treatment of advanced NSCLC.
      However, several trials comparing platinum versus non-platinum based chemotherapy regimens
      failed to demonstrate a statistically significant difference in terms of time to tumor
      progression or survival. Newer agents such as gemcitabine, docetaxel and vinorelbine have
      shown significant activity in the treatment of NSCLC. Gemcitabine/vinorelbine combination as
      first line treatment has demonstrated a response rate (RR) of 18-43% and a median overall
      survival (OS) of 9.8-13 months. Similarly, the gemcitabine/docetaxel combination has shown a
      RR 32-35% and a median OS of 9-12 months. Given their proven efficacy, the combination of
      these two doublets, would be interesting.
    

Intervention name(s): Vinorelbine; Gemcitabine; Docetaxel; Gemcitabine
Intervention type(s): Drug; Drug; Drug; Drug
Intervention description(s): Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles; Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles; Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles; Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
Other intervention name(s): Navelbine; Gemzar; Taxotere; Gemzar
Intervention MeSH terms: Gemcitabine; Docetaxel; Vinorelbine
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment
Keywords: NSCLC; 1st line treatment; Gemcitabine; Vinorelbine; Docetaxel
Schizophrenia Trial of Aripiprazole
Condition: Schizophrenia
MeSH terms: Schizophrenia
Study type: Interventional
Phase: Phase 3

Summary: 
      Aripiprazole will show improved effectiveness over the standard of care treatment with one of
      three atypical antipsychotics (olanzapine, quetiapine and risperidone).
    


Intervention name(s): Aripiprazole; Olanzapine or Quetiapine or Risperidone
Intervention type(s): Drug; Drug
Intervention description(s): Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.; Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
Other intervention name(s): Abilify
Intervention MeSH terms: Olanzapine; Risperidone; Aripiprazole; Quetiapine Fumarate
Allocation: Randomized
Intervention model: Parallel Assignment
Masking: None (Open Label)
Primary purpose: Treatment